Metabolic effects of antipsychotic drugs
https://doi.org/10.14341/2071-8713-4966
References
1. Gury C. Schizophrenia, diabetes mellitus and antipsychotics. Encephale. 2004 Jul-Aug;30(4):382–91.
2. Weiden P, Mackell J, McDonnell D. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Res. 2004;66:51–57.
3. Fiedorowicz J, Miller D, Jeffrey R, Chadi A, Ellingrod L, William G. Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev. 2012;8(1):25–36.
4. Newcomer J. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 (Suppl 1):1–93.
5. Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias M, Hernаndez L. Antipsychotic Drugs and Obesity: Is Prolactin Involved? Can J Psychiatry. 2001;46:829–834.
6. Melkersson K, Berinder K, Hulting A. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. Neuro Endocrinol Lett. 2011;32(4):428–36.
7. Lieberman J. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine. 2005;353:1209–23.
8. Haupt D, Newcomer J. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62 Suppl 27:15–26; discussion 40–1.
Review
For citations:
, Metabolic effects of antipsychotic drugs. Obesity and metabolism. 2012;9(3):11-13. (In Russ.) https://doi.org/10.14341/2071-8713-4966
Views:
379
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
